07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CX3C motif receptor 1 (CX3CR1)

Inflammation INDICATION: Shock / trauma Mouse studies suggest inhibiting CX3CR1 could help treat the chronic phase of traumatic brain injury (TBI). In a mouse model of chronic-phase TBI, CX3CR1 knockout decreased lesion size, hippocampal damage...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Anti-CX3CR1 Nanobody: Phase I started

Boehringer began a Phase I trial to evaluate single ascending doses of IV anti-CX3CR1 Nanobody. The start triggered a EUR8 million ($9 million) milestone payment to Ablynx from Boehringer under a 2007 deal to use...